Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
about
Clinical Scenarios for Discordant Anti-XaThe Anti-Factor Xa Range For Low Molecular Weight Heparin ThromboprophylaxisPrevention of venous thromboembolism in patients undergoing bariatric surgeryPhysiological and management implications of obesity in critical illnessMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewA systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyPharmacology of anticoagulants used in the treatment of venous thromboembolismGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismSelecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma.Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH.Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingAppropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.Cancer-associated thrombosis: an overviewMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case seriesRecent advances in the diagnosis and treatment of acute myocardial infarctionPrevention of venous thromboembolism in obesity.Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.Clinical and critical care concerns in severely ill obese patient.Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing.Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Low-molecular-weight heparin overdose: management by observation.New and generic anticoagulants and biosimilars: safety considerations.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.A clinician's guide to perioperative bridging for patients on oral anticoagulation.Anticoagulating obese patients in the modern era.Perioperative management of morbid obesity.Stone management for the patient on anticoagulation.Anticoagulant use in real time.Pharmacologic prevention of venous thromboembolism in obese patients.Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.Considerations for Systemic Anticoagulation in ESRD.Risks and benefits of low molecular-weight heparin and target-specific oral anticoagulant use for thromboprophylaxis in medically ill patients.Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.
P2860
Q26746987-A1111050-60F7-4011-A579-4501458D6813Q26770822-6AB490B8-9AC2-46CC-B066-CF7160674D7FQ26796429-29D2FEE0-2F6A-4CA4-952D-2629561EC9E3Q26830471-C23C0E68-BABB-499B-85A1-4CB7ED2D282AQ26992262-059ADBAF-46C9-456D-B696-EF104FF78A0AQ26995027-95A3A63C-DDF4-458B-9749-9318D4457E47Q28078967-B9BF7BD3-4A34-4FF3-96D7-6B92921909CDQ28079081-1A21A14D-887A-4730-BEBE-F657CFD7C219Q30438893-99CA3A6B-B1A6-4A28-BB63-71E82B50EF4FQ33393653-52C6A1B6-5BFF-4992-8373-66B916F25445Q33416926-5E5E4047-AECA-4692-915D-0A5F2CF5D708Q33569992-C78E8947-9402-4D58-AE3F-989824D5EC66Q33763123-353921E0-F860-424B-8ACA-6AA36BFEE26AQ34207558-C77FC8BE-4005-4214-A54B-512AA53585B3Q34612869-FB068B75-D005-4AA1-843E-CE41E8F43AB2Q34655217-F4DD97AF-427F-40F1-AF5E-3830A296C306Q35154142-F0713777-F13C-4903-83DB-82049CD161B2Q35626540-3CC9D872-C8D0-4586-879C-4F04477FBD84Q35626702-1565F540-B612-4650-B65E-373611042D71Q35633708-903AEC94-581A-47B5-B0DE-D39057E4E35CQ36205646-2A2C6BE2-DD88-4D78-865D-0E76CF22F454Q36331619-68AC92E7-C333-418B-A497-104EFCA6C996Q37067436-E1886890-7A05-4172-8E8D-FBBC61FE9208Q37353441-A9E94166-6672-4CCD-84AF-37D4CE5D5681Q37798093-8276CA8E-A9FC-4370-B12A-9F397FA373E2Q37821142-9BC8787F-106A-45CF-8ABA-AC68EC874410Q37844143-F1EAB3FA-CBC2-42BB-8D64-DD96F7B0BA1FQ37867286-DAD68C5B-6692-4395-9F98-972E91A2326DQ37919151-5D6652FF-BB9B-4B10-8AE1-61823165141DQ37923469-829C0CE6-B268-42C0-8F59-FE731E100C54Q37993477-BEF057B7-D9F9-4F47-BDAD-E7207454FF4EQ38062284-4ADC88CE-189A-4DC5-8CD5-A342113A2BFFQ38062477-E8212F1E-DD41-4220-B8DA-A6AA932F109CQ38107945-9442FECB-BAF8-4AF8-AB30-882D96906563Q38464975-00D8E3EB-9492-45B6-ACE8-58CB31DCA93BQ38468532-A246851D-1CCE-48B4-ADEE-D69786049032Q38485825-CBDDD753-8415-429D-A75F-B8F75EA9F0A3Q38633482-69B3C13B-0ACA-4094-B7BA-7EEEB9B540D5Q38944457-62C59DD2-5390-4AC7-93D6-EF81E7EBC763Q39601367-2035D22A-24C5-477B-BB87-CD0FA879B96A
P2860
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low-molecular-weight heparins ...... medical and surgical settings.
@en
Low-molecular-weight heparins ...... medical and surgical settings.
@nl
type
label
Low-molecular-weight heparins ...... medical and surgical settings.
@en
Low-molecular-weight heparins ...... medical and surgical settings.
@nl
prefLabel
Low-molecular-weight heparins ...... medical and surgical settings.
@en
Low-molecular-weight heparins ...... medical and surgical settings.
@nl
P2093
P2860
P356
P1476
Low-molecular-weight heparins ...... medical and surgical settings.
@en
P2093
Ann Wittkowsky
Edith A Nutescu
Sarah A Spinler
William E Dager
P2860
P304
P356
10.1345/APH.1L194
P407
P577
2009-05-19T00:00:00Z